RoundTable divests Renaissance’s topical pharma unit
June 17, 2016
RoundTable Healthcare Partners has closed the sale of Renaissance Acquisition’s topical pharmaceutical business to Mylan, a generic & specialty pharma company, for $950 million in cash. The deal includes additional contingent payments of up to $50 million. RoundTable formed Renaissance in 2010 when the firm acquired two contract manufacturing and development organizations.